| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.13B | 27.09B | 23.28B | 22.55B | 20.09B | 18.67B |
| Gross Profit | 13.32B | 10.77B | 8.87B | 10.96B | 7.41B | 10.08B |
| EBITDA | 3.98B | 3.99B | 3.08B | 3.32B | 3.55B | 2.21B |
| Net Income | 3.27B | 3.47B | 2.67B | 3.10B | 3.09B | 1.19B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 64.42B | 61.48B | 58.33B | 56.92B | 56.66B |
| Cash, Cash Equivalents and Short-Term Investments | 1.09B | 1.29B | 3.16B | 1.08B | 1.96B | 2.52B |
| Total Debt | 0.00 | 1.88B | 3.29B | 2.97B | 3.87B | 5.50B |
| Total Liabilities | -56.72B | 7.70B | 7.91B | 7.11B | 8.48B | 10.99B |
| Stockholders Equity | 56.72B | 56.72B | 53.58B | 51.23B | 48.44B | 45.68B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 3.14B | 2.18B | 467.00M | 1.61B | 2.67B |
| Operating Cash Flow | 0.00 | 3.80B | 2.46B | 917.00M | 2.37B | 2.87B |
| Investing Cash Flow | 0.00 | -2.24B | -1.78B | -849.00M | -859.50M | -104.10M |
| Financing Cash Flow | 0.00 | -1.86B | -257.00M | -1.39B | -2.34B | -2.16B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ₹129.15B | 31.85 | ― | 0.26% | 5.73% | -7.74% | |
66 Neutral | ₹70.82B | 51.95 | ― | 0.45% | 10.82% | -8.21% | |
66 Neutral | ₹141.63B | 55.89 | ― | 0.28% | 14.55% | -20.61% | |
66 Neutral | ₹69.63B | 26.13 | ― | 0.77% | 24.93% | 20.57% | |
64 Neutral | ₹175.87B | 82.63 | ― | 0.13% | 11.04% | -26.83% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | ₹95.75B | 27.49 | ― | 1.24% | 1.62% | -7.32% |
Zydus Wellness Limited has announced that its trading window will be closed from January 1, 2026 until 48 hours after the declaration of its unaudited financial results for the quarter and nine months ending December 31, 2025. The restriction, applicable to directors, designated persons and their immediate relatives, is in line with SEBI’s insider trading regulations and reflects the company’s compliance and governance framework ahead of its upcoming earnings announcement, for which the board meeting date will be communicated separately.
Zydus Wellness Limited has announced a disclosure under the SEBI (Prohibition of Insider Trading) Regulations, 2015, pertaining to the acquisition of equity shares by its CEO and Whole Time Director, Mr. Tarun Arora. Mr. Arora acquired 1,000 equity shares from the open market, increasing his total shareholding to 11,000 shares. This move is part of the continual disclosure requirements under the SEBI regulations, ensuring transparency and compliance with insider trading laws.
Zydus Wellness Limited announced the release of the transcript from its Q2 FY2026 earnings conference call, which was held on November 5, 2025. This disclosure, in compliance with SEBI regulations, provides stakeholders with insights into the company’s financial performance and strategic direction, potentially impacting investor confidence and market positioning.
Zydus Wellness Limited has received an ESG rating of ’73’ with a grade of B+ and category ‘Very Good’ from CFC Finlease Private Limited, based on publicly available information. This rating reflects positively on the company’s commitment to environmental, social, and governance standards, potentially enhancing its reputation and appeal among stakeholders and investors.